Today's Highlights
Premium
Why Alder Biopharmaceuticals Stock Gained Over 83%. See Also: Prohost Picked Stocks Outperforming in a Down Market Day
Migraine's Really Effective Treatments The years 2018 and 2019 could be called the years of migraine’s really effective treatments. Three Calcitonin-gene-related peptide ( CGRP ) monoclonal antibody d...
P
Prohost Biotech
1 min read
18
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Tags
Alder BioPharmaceuticals (ALDR)
Alnylam Pharmaceuticals (ALNY)
Amgen (AMGN)
CRISPR Therapeutics (CRSP)
Editas Medicine Inc (EDIT)
Eli Lilly (LLY)
Incyte (INCY)
Intellia Therapeutics (NTLA)
Moderna Inc (MRNA)
Regenxbio (RGNX)
Seagen Inc (SGEN)
Teva Pharmaceutical Industries Ltd (TEVA)
Vertex Pharmaceuticals (VRTX)
Comments (0)
Please sign in to join the discussion